Oraxol (oral paclitaxel/encequidar) / Athenex 
Welcome,         Profile    Billing    Logout  
 0 Diseases   4 Trials   4 Trials   235 News 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Oraxol (oral paclitaxel/encequidar) / Athenex
2017-004578-33: A Safety Study of Oraxol in Cancer Patients

Not yet recruiting
2
40
Europe
Oraxol, HM30181AK-US, paclitaxel capsules, paclitaxel tablets, Tablet, Capsule, hard
Athenex, Inc., Athenex, Inc
Cancer patients for whom treatment with IV paclitaxel at 80 mg/m2 has been recommended by their oncologist, either as monotherapy or in combination with other agents, Cancer, Diseases [C] - Cancer [C04]
 
 
2019-002085-13: A Pilot Study of Oraxol in Subjects with Cutaneous Angiosarcoma

Not yet recruiting
2
43
Europe
Oraxol, HM30181AK-US, paclitaxel capsules, Tablet, Capsule, hard
Athenex, Inc, Athenex, Inc
Study of Oraxol in Subjects with Cutaneous Angiosarcoma, Soft tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
KX-ORAX-010 , NCT03544567: A Study of Oraxol in Subjects With Cutaneous Angiosarcoma

Completed
2
48
Europe, US, RoW
Oraxol, oral HM30181A + oral paclitaxel
Athenex, Inc.
Angiosarcoma of Skin
05/23
05/23
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT02970539: Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Active, not recruiting
1b
36
US, RoW
Oraxol, oral HM30181AK-US tablet and paclitaxel capsule, Ramucirumab, LY3009806
Athenex, Inc.
Gastric Cancer, Esophageal Cancer, Gastro-esophageal Cancer
03/19
12/22
ACTRN12614000365662: An Open-label, Randomized Cross-over, Pharmacokinetic Study to Determine the Bioavailability, Safety, and Tolerability of Two Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel Amendment 1

Recruiting
1
8
 
Kinex Pharmaceuticals, Inc., Kinex Pharmaceuticals, Inc.
Cancer
 
 
ChiCTR1900021427: A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

Not yet recruiting
1
24
 
Drug therapy
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, sponsor
Breast Cancer
 
 
KEYNOTE-E06, NCT03588039: Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

Checkmark Interim data in combination with Paclitaxel for NSCLC and advance solid tumor at ESMO
Sep 2021 - Sep 2021: Interim data in combination with Paclitaxel for NSCLC and advance solid tumor at ESMO
Terminated
1
34
US
Oraxol, oral HM30181A + oral paclitaxel, Pembrolizumab, Keytruda
Athenex, Inc., Merck Sharp & Dohme LLC
Solid Tumor
05/23
05/23
NCT03892018: The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol

Terminated
1
29
Europe
Oraxol, Paclitaxel and HM30181AK-US
Athenex, Inc.
Solid Tumor, Adult
05/23
05/23

Download Options